• 1
    Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation 2001; 72: 764769.
  • 2
    Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569575.
  • 3
    Tedesco-Silva H, Mourad G, Kahan BD et al.. FTY720, a novel immunomodulator – efficacy and safety results from the first Phase 2a study in de novo renal transplantation. Transplantation 2004.
  • 4
    Adachi K, Kohara T, Nakao N et al.. Design, synthesis and structure-activity relationships of 2-substituted 2-amino- 1,3-propanediols: Discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995; 5: 853856.
  • 5
    Chen JK, Lane WS, Schreiber S. The identification of myriocin-binding proteins. Chem Biol 1999; 6: 221235.
  • 6
    Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 57615770.
  • 7
    Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000; 21: 4952.
  • 8
    Chiba K, Yanagawa Y, Masubuchi Y et al.. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 50375044.
  • 9
    Bai Y, Liu J, Wang Y et al.. 1-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol 2002; 168: 15791589.
  • 10
    Henning G, Ohl L, Junt T et al.. CC Chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 2001; 194: 18751881.
  • 11
    Muller G, Reiterer P, Hopken UE, Golfier S, Lipp M. Role of homeostatic chemokine and sphingosine-1-phosphate receptors in the organization of lymphoid tissue. Ann N Y Acad Sci 2003; 987: 107116.
  • 12
    Brinkmann V, Davis MD, Heise CE et al.. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 2145321457.
  • 13
    Mandala S, Hajdu R, Bergstrom J et al.. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 2002; 296: 346349.
  • 14
    Matloubian M, Lo C, Cinnamon G et al.. Lymphocyte egress from thymus and peripheral lymphoid organs is sphingosine 1-phosphate receptor-1 dependent. Nature 2004; 427: 355360.
  • 15
    Kimura T, Sato K, Kuwabara A et al.. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276: 3178031785.
  • 16
    English D, Welch Z, Kovala AT et al.. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000; 14: 22552265.
  • 17
    Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T. The balance between sphingosine and sphingosine-1-phosphate is decisive for mast-cell activation after Fc epsilon receptor I triggering. J Exp Med 1999; 190: 18.
  • 18
    Ancellin N, Colmont C, Su J et al.. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002; 277: 66676675.
  • 19
    Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids-receptor revelations. Science 2001; 294: 18751878.
  • 20
    Sanchez T, Estrada-Hernandez T, Paik JH et al.. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278: 4728147290.
  • 21
    Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134140.
  • 22
    Yagi H, Kamba R, Chiba K et al.. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000; 30: 14351444.
  • 23
    Graeler MH, Goezl EJ. The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G protein-coupled receptors. FASEB J 2004 (Epub ahead of print).
  • 24
    Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell 1999; 10: 11791190.
  • 25
    Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. FTY720 prolongs skin allograft survival by decreasing T-cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 54935499.
  • 26
    Hwang MW, Matsumori A, Furukawa Y et al.. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 1999; 100: 13221329.
  • 27
    Fu F, Hu S, Deleo J et al.. Long-term islet graft survival in STZ and autoimmune induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73: 14251430.
  • 28
    Yang Z, Chen M, Fialkow LB et al.. The immune modulator FTY720 prevents autoimmune diabetes in nonobese diabetic mice. Clin Immunol 2003; 107: 3035.
  • 29
    Fujino M, Funeshima N, Kitazawa Y et al.. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 7077.
  • 30
    Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ, Rosen H. Sphingosine-1-phosphate receptor agonist impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T-cells. J Immunol 2003; 170: 36623670.
  • 31
    Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003; 111: 659669.
  • 32
    Miyamoto T, Matsumori A, Hwang MW, Nishio R, Ito H, Sasayama S. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol 2001; 37: 17131718.
  • 33
    Schuurman HJ, Menninger K, Audet M et al.. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74: 951960.
  • 34
    Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 24132417.
  • 35
    Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3: 269279.
  • 36
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708712.
  • 37
    Nikolova Z, Hof A, Baumlin Y, Hof RP. Efficacy of SDZ RAD compared with CsA monotherapy and combined RAD/FTY720 treatment in a murine cardiac allotransplantation model. Transpl Immunol 2001; 9: 4349.
  • 38
    Allende ML, Yamashita T, Proia RL. G-protein coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 2003; 102: 36653667.
  • 39
    Lee MJ, Thangada S, Claffey KP et al.. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301312.
  • 40
    Schaphorst KL, Chiang E, Jacobs KN et al.. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 2003; 285: 258267.
  • 41
    Nofer JR, Van der Giet M, Toelle M et al.. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3: role of HDL-associated lysophospholipids. J Clin Invest 2004; 113: 569581.
  • 42
    Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001; 91: 14871500.
  • 43
    Bassenge E. Endothelial function in different organs. Prog Cardiovasc Dis 1996; 39: 209228.
  • 44
    Labarrere CA, Nelson DR, Park JW. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol 2001; 16: 110117.
  • 45
    Cooper D, Stokes KY, Tailor A, Granger DN. Oxidative stress promotes blood cell–endothelial cell interactions in the microcirculation. Cardiovasc Toxicol 2002; 2: 165180.
  • 46
    Nikolova Z, Hof A, Rudin M, Baumlin Y, Kraus G, Hof RP. Prevention of graft vessel disease by combined FTY720 and Cyclosporin A treatment in the DA to Lewis rat carotid artery transplantation model. Transplantation 2000; 69: 25252530.
  • 47
    Anselmo DM, Amersi FF, Shen XD et al.. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2002; 2: 843849.
  • 48
    Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 2003; 284: 20452052.
  • 49
    Forrest M, Sun SY, Hajdu R et al.. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor sub-types. J Pharmacol Exp Ther 2004 (Epub ahead of print).
  • 50
    Sanna MG, Liao J, Jo E et al.. Distinct S1P receptor subtypes S1P1 and S1P3 respectively regulate lymphocyte recirculation and heart rate. J Biol Chem 2004 (Epub ahead of print).
  • 51
    Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002; 50: 661670.
  • 52
    Liliom K, Sun G, Bunemann M et al.. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 2001; 355: 189197.
  • 53
    Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch 1999; 438: 642648.
  • 54
    Bunemann M, Brandts Bzu Heringdorf DM, Van Koppen CJ, Jakobs KH, Pott L. Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate. J Physiol 1995; 489: 701777.
  • 55
    Yamada M. The role of muscarinic K(+) channels in the negative chronotropic effect of a muscarinic agonist. J Pharmacol Exp Ther 2002; 300: 681687.
  • 56
    Jan LY, Jan YN. Heartfelt crosstalk: desensitization of the GIRK current. Nat Cell Biol 2000; 2: 165167.
  • 57
    Tawadrous MN, Mabuchi A, Zimmermann A, Wheatley AM. Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. Transplantation 2002; 74: 602610.